Colorectal tumor vascularity: Quantitative assessment with multidetector CT-Do tumor perfusion measurements reflect angiogenesis?

Radiology

Volumn 249, Issue 2, 2008, Pages 510-517

  Goh, Vicky ^a   Halligan, Steve ^c   Daley, Frances ^b   Wellsted, David M ^d   Guenther, Thomas ^e   Bartram, Clive I ^f  

^a Paul Strickland Scanner Centre   (United Kingdom)

^b Gray Cancer Institute   (United Kingdom)

^c MOUNT VERNON HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^e UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^f ST MARK S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE TRANSPORTER 1; VASCULOTROPIN; CONTRAST MEDIUM; DIAGNOSTIC AGENT; IOPAMIDOL; TUMOR MARKER; VASCULOTROPIN A;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CLINICAL ARTICLE; COLORECTAL TUMOR; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; VASCULAR TUMOR; ADENOCARCINOMA; BLOOD FLOW VELOCITY; COMPUTER ASSISTED DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; METHODOLOGY; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); NONPARAMETRIC TEST; RADIOGRAPHY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BLOOD FLOW VELOCITY; COLORECTAL NEOPLASMS; CONTRAST MEDIA; FEMALE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; IMMUNOHISTOCHEMISTRY; IOPAMIDOL; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; RADIOGRAPHIC IMAGE INTERPRETATION, COMPUTER-ASSISTED; STATISTICS, NONPARAMETRIC; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 56149090049     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2492071365     Document Type: Article

References (44)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186.
2. Ajiki T, Fujimori T, Ikehara H, Saitoh Y, Maeda S. K-ras gene mutation related to histological atypias in human colorectal adenomas. Biotech Histochem 1995;70:90-94.
3. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Sasazuki T, Kerbel RS. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995;55:4575-4580.
4. Konerding MA, Fait E, Gaumann A. 3D microvascular architecture of pre-cancerous lesions and invasive carcinomas of the colon. Br J Cancer 2001;84:1354-1362.
5. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
6. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-147.
7. Yi CA, Lee KS, Kim EA, et al. Solitary pulmonary nodules: dynamic enhanced multidetector row CT study and comparison with vascular endothelial growth factor and microvessel density. Radiology 2004;233:191-199.
8. Tateishi U, Kusumoto M, Nishihara H, Nagashima K, Morikawa T, Moriyama N. Contrast enhanced dynamic computed tomography for the evaluation of angiogenesis in patients with lung carcinoma. Cancer 2002;95:835-842.
9. Wang JH, Min PQ, Wang PJ, et al. Dynamic CT evaluation of tumor vascularity in renal cell carcinoma. AJR Am J Roentgenol 2006;186:1423-1430.
10. St Lawrence KS, Lee TY. An adiabatic approximation to the tissue homogeneity model for water exchange in the brain. I. Theoretical derivation. J Cereb Blood Flow Metab 1998;18:1365-1377.
11. Beresford MJ, Harris AL, Ah-See M, Daley F, Padhani AR, Makris A. The relationship of the neo-angiogenic marker, endoglin, with response to neoadjuvant chemotherapy in breast cancer. Br J Cancer 2006;95:1683-1688.
12. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis: correlation in invasive breast cancer. N Engl J Med 1991;324:1-8.
13. Ng QS, Goh V, Milner J, et al. Effect of nitricoxide synthesis on tumour blood volume and vascular activity: a phase I study. Lancet Oncol 2007;8:111-118.
14. Meijerink MR, van Cruijsen H, Hoekman K, et al. The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefinitib in cancer patients. Eur Radiol 2007;17:1700-1713.
15. Ng QS, Goh V, Carnell D, et al. Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human nonsmall-cell lung cancer. Int J Radiat Oncol Biol Phys 2007;67:1375-1380.
16. Sahani DV, Kalva SP, Hamberg LM, et al. Assessing tumor perfusion and treatment response in rectal cancer with multisection CT: initial observations. Radiology 2005;234:785-792.
17. Hermans R, Meijerink M, Van den Bogaert W, et al. Tumor perfusion rate determined noninvasively by dynamic computed tomography predicts outcome in head-and-neck cancer after radiotherapy. Int J Radiat Oncol Biol Phys 2003;57:1351-1356.
18. Li ZP, Meng QF, Sun CH, et al. Tumor angiogenesis and dynamic CT in colorectal carcinoma: radiologic-pathologic correlation. World J Gastroenterol 2005;11:1287-1291.
19. Tuncbilek N, Karakas HM, Altaner S. Dynamic MRI in indirect estimation of microvessel density, histologic grade, and prognosis in colorectal adenocarcinomas. Abdom Imaging 2004;29:166-172.
20. Atkin G, Taylor NJ, Daley FM, et al. Dynamic contrast-enhanced magnetic resonance imaging is a poor measure of colorectal cancer angiogenesis. Br J Surg 2006;93:992-1000.
21. Kan Z, Phongkitkarun S, Koyabashi S, et al. Functional CT for quantifying tumor perfusion in antiangiogenic therapy in a rat model. Radiology 2005;237:151-158.
22. Drevs J, Muller-Driver R, Wittig C, et al. PTK787/ZK222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res 2002;62:4015-4022.
23. Eberhard A, Kahlert S, Geode V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 2000;60:1388-1393.
24. Tatum JL, Kelloff GJ, Gillies RJ, et al. Hypoxia: importance in tumor biology, non-invasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 2006;82:699-757.
25. Folkman J. Fundamental concepts of the angiogenic process. Curr Mol Med 2003;3:643-651.
26. Des Guetz G, Uzzan B, Nicolas P, et al. Microvessel density and VEGF expression are prognostic factors in colorectal cancer: metaanalysis of the literature. Br J Cancer 2006;94:1823-1832.
27. Werther K, Christensen IJ, Brunner N, Nielsen HJ. Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma: the Danish RANX05 Colorectal Cancer Study Group. Eur J Surg Oncol 2000;26:657-662.
28. George ML, Dzik-Jurasz AS, Padhani AR, et al. Non invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer. Br J Surg 2001;88:1628-1636.
29. Airley R, Loncaster J, Davidson S, et al. Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasisfree survival in advanced carcinoma of the cervix. Clin Cancer Res 2001;7:928-934.
30. Kato H, Takita J, Miyazaki T, et al. Glut-1 glucose transporter expression in esophageal squamous cell carcinoma is associated with tumor aggressiveness. Anticancer Res 2002;22:2635-2639.
31. Cooper R, Sarioglu S, Sokmen S, et al. Glucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma? Br J Cancer 2003;89:870-876.
32. Furudoi A, Tanaka S, Haruma K, et al. Clinical significance of human erythrocyte glucose transporter 1 expression at the deepest invasive site of advanced colorectal carcinoma. Oncology 2001;60:162-169.
33. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 2002;94:883-893.
34. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
35. Offersen BV, Borre M, Overgaard J. Quantification of angiogenesis as a prognostic marker in human carcinomas: a critical evaluation of histopathological methods for estimation of vascular density. Eur J Cancer 2003;39:881-890.
36. Vermeulen PB, Gasparini G, Fox SB, et al. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer 2002;38:1564-1579.
37. de Jong JS, van Diest PJ, Baak JP. Heterogeneity and reproducibility of microvessel counts in breast cancer. Lab Invest 1995;73:922-926.
38. Axelsson K, Ljung BM, Moore DH 2nd, et al. Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J Natl Cancer Inst 1995;87:997-1008.
39. Belien JA, Somi S, de Jong JS, van Diest PJ, Baak JP. Fully automated microvessel counting and hot spot selection by image processing of whole tumour sections in invasive breast cancer. J Clin Pathol 1999;52:184-192.
40. Goh V, Halligan S, Hugill JA, Bartram CI. Quantitative assessment of colorectal cancer perfusion using MDCT: inter- and intra-observer agreement. AJR Am J Roentgenol 2005;185:225-231.
41. Goh V, Halligan S, Hugill JA, Gartner L, Bartam CI. Quantitative colorectal cancer perfusion measurement using dynamic contrast enhanced multidetector-row computed tomography: effect of acquisition time and implications for protocols. J Comput Assist Tomogr 2005;29:59-63.
42. Goh V, Halligan S, Bartram CI. Quantitative tumor perfusion assessment with multidetector CT: are measurements from two commercial software packages interchangeable? Radiology 2007;242:777-782.
43. Goh V, Halligan S, Hugill JA, Bartram CI. Quantitative assessment of tissue perfusion using MDCT: comparison of colorectal cancer and skeletal muscle measurement reproducibility. AJR Am J Roentgenol 2006;187:164-169.
44. Goh V, Halligan S, Gartner L, Bassett P, Bartram CI. Quantitative assessment of colorectal cancer perfusion by MDCT: does greater tumour coverage improve measurement reproducibility? Br J Radiol 2006;79:578-583